尤瑞克林治疗高龄急性脑梗死患者疗效观察

Effect of Urinarykallikrein in Elderly Patients with Acute Ischemic Stroke

目的观察尤瑞克林治疗高龄急性脑梗死患者(年龄≥75岁)的临床疗效。方法收集年龄≥75岁的急性脑梗死患者201例,按随机数字表法分为尤瑞克林组(1 00例)和对照组(101例)。两组患者根据病情,给予相同的基础治疗,尤瑞克林组在此基础上给予每天0.15 PNA U尤瑞克林(100 ml生理盐水稀释,静脉滴注,qd,共14 d),对照组给予空白生理盐水1 00 ml静脉滴注,qd,共14 d。在治疗前及治疗后第14 d,比较两组患者美国国立卫生院卒中量表(National Institute 0fHealth stroke scale,NIHSS)评分和临床总有效率。结果与治疗前相比,两组治疗后NIHSS评分均下降(尤瑞克林组:4.55±2.89vs 2.54±1.96,t=7.261,P=0.002;对照组:4.11±2.56 vs 3.49±2.55,t=7.439,P=0.01 3),治疗后尤瑞克林组患者NIHSS评分低于对照组(t=2.093,P=0.023),临床总有效率高于对照组(84%vs 55%,U=2896,P=0.001)。结论尤瑞克林能促进高龄急性脑梗死患者的神经功能恢复,提高疗效,值得临床推广使用。

Objective To observe the effect ofurinarykallikrein in elderly patients with acute ischemic stroke. Methods Two hundred and one elderly patients（age≥ 75） with acute ischemic stroke were admitted to our hospital from July 2008 to November 2010. They were enrolled in the randomized single-blind control trail. These patients were assigned to urinarykallikrein treatment group（n= 100） and control group（n=101）. They were both treated by identical basis therapy. The patients in the treatment group were treated by intravenous infusion administration of 0.15 PNA U urinarykallikrein diluted in 100ml 0.9% saline, once daily for 14 consecutive days. On the pre- therapy and 14st post-treatment day, the two groups were compared with the National Institutes of Health Stroke Scale（NIHSS） score and total clinical efficiency. Results After 14d treatment, NIHSS of both urinarykallikrein and control group were decreased as compared with the pretreatment （urinarykallikrein, 4.55±2.89 vs 2.54±1.96, t=-7.261, P=0.002; control, 4.11±2.56 vs 3.49：L2.55, t=-7.439, P=0.013）. The decrease of NIHSS in urinarykallikrein group was more significant than that in control group（t=2.093, P=0.023）, the rate of total clinical efficiency in treatment group is greater than that in the control group（84% vs 55%, U=2896, P=0.001）. Conclusion Urinarykallikrein is effective for the treatment of elderly patients with acute ischemic stroke, so it is worthy to be recommended for clinical application for elderly patients.